AC Immune
Yves Kremer has extensive experience in clinical research, data analysis, and brain imaging in various prestigious institutions. Currently, Yves holds a managerial position at AC Immune, focusing on investor communication, competitive intelligence, and scientific messaging in the neurodegeneration field. Prior to this role, Yves was a Clinical Scientist at GTX medical, where Yves conducted assessments on therapeutic benefits for spinal cord injury rehabilitation. Additionally, Yves has a background in deep brain recordings in Parkinson's disease patients and sensory perception research.
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.